A newly identified ERCC6-like gene in mice, ERCC6L, also known as polo-like kinase 1 (PLK1)-interacting checkpoint helicase, has been demonstrated to be a development-associated member of the SNF2 family. Excision repair cross-complementation group 6 like (ERCC6L) is highly expressed in a variety of human cancer types. The ERCC6L protein is assembled in the cytoplasm and then enters the cell nucleus to exert its function. It is strongly expressed in the mouse embryonic stage, particularly in embryonic brain, heart, kidney, liver and lung. ERCC6L silencing has been revealed to inhibit the proliferation of cancer cells, which suggests that ERCC6L may be an effective biomarker for cancer progression.